ASCO 2015: Latest developments in prostate cancer treatment

Bookmark and Share
Published: 31 May 2015
Views: 5632
Prof Cora Sternberg, Prof Noel Clarke, Prof Eleni Efstathiou, Prof Karim Fizazi

Prof Sternberg (San Camillo and Forlanini Hospitals, Rome, Italy) chairs a discussion at ASCO 2015 for ecancertv with Prof Clarke (The Christie Hospital, Manchester, UK), Prof Efstathiou (MD Anderson Cancer Center, Houston, USA), and Prof Fizazi (Institut Gustave Roussy, Paris, France) about the latest in novel agents and treatment strategies for prostate cancer.

They consider the evolving landscape of castration-resistant prostate cancer (CRPC) treatment and give insight into potential treatments for use in late-stage disease, with a particular focus on new data that has arisen from the ASCO 2015 conference.

In particular, they discuss the docetaxel chemo combination that has seen significant survival benefits, the merits of androgen deprivation therapy in early versus late stage disease, and the need for genomic molecular classifications that move beyond the Gleason score.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).